A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults

Marvin J. Sklar, Santina Maiolatesi, Noelle Patterson, Martha Sedegah, Keith Limbach, Nimfa Teneza-Mora, Ilin Chuang, K. Monique Hollis-Perry, Jo Glenna Banania, Ivelese Guzman, Harini Ganeshan, Sharina Reyes, Michael R. Hollingdale*, Mimi Wong, Ashley Lindstrom, Anatalio Reyes, Yolanda Alcorta, Lindsey Garver, Kelli Bankard, Arnel BelmonteMaria Belmonte, Jun Huang, Kalpana Gowda, Sandra Inoue, Rachel Velasco, Elke Bergmann-Leitner, Jack Hutter, Tida Lee, Nehkonti Adams, Sidhartha Chaudhury, Devin Hunt, Cindy Tamminga, Eleanor Berrie, Duncan Bellamy, Mustapha Bittaye, Katie Ewer, Carter Diggs, Lorraine A. Soisson, Alison Lawrie, Adrian Hill, Thomas L. Richie, Eileen Villasante, Judith E. Epstein, Christopher A. Duplessis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults'. Together they form a unique fingerprint.

Medicine & Life Sciences